Spectrum Dynamics Medical has gained US Food and Drug Administration (FDA) clearance for the Veritas.AI Noise Reduction platform, setting the company up to advance the performance capabilities of its VERITON-CT SPECT/CT nuclear imaging system.
Veritas.AI uses a deep learning convolutional neural network (CNN) that is designed to reduce image noise while preserving spatial resolution and quantitative accuracy. According to Spectrum Dynamics, the platform has been clinically validated for applications and tracers including bone imaging and Lu-177 theranostics, a treatment for prostate cancer patients, and will reduce VERITON-CT scan time by up to 50%.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The platform is also expected to improve VERITON-CT’s image quality in low-count and high-noise conditions within what Spectrum describes as some of nuclear medicines’ “most demanding” imaging scenarios.
Spectrum Dynamics’ CEO Tomer Gabay commented: “Veritas.AI strengthens our commitment to precision imaging by delivering clearer images, greater clinical confidence, and more efficient workflows, while helping hospitals prepare for the rapid growth of theranostics and quantitative SPECT/CT.”
Recent developments in nuclear imaging
At the recent JP Morgan Healthcare Conference, GE HealthCare announced plans to scale its nuclear imaging portfolio. According to GlobalData analysis, the imaging giant holds an estimated 34% share of the positron emission tomography (PET) and single-photon emission computed tomography (SPECT) equipment market.
Commenting on GE HealthCare’s plans to scale, GlobalData analysts note that management’s discussion of PET Omni – the company’s main PET-CT system that was introduced in 2022 – and other pipeline products fit a strategy of “staying ahead in equipment” but also using its installed base to support “recurring, procedure-linked revenue”.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAdditional GlobalData analysis on nuclear imaging highlights that the field is going through a notable period of change. According to the analysis, PET scans are gaining traction in oncology and other high-value applications – a factor that is being driven by innovations in tracer development, theranostics, and advanced imaging technologies. As per GlobalData analysis, the PET imaging agent market still lags SPECT, valued at $2.1bn in 2025, compared to $4.7bn for SPECT. However, between 2025 and 2035, PET agents are projected to grow at a CAGR of 4.6%, representing a rate 5.5 times higher than the projected growth of SPECT agents.
Meanwhile, the overall global nuclear imaging market is growing at a CAGR of 7.8% and projected to almost double in value to $10.10bn in 2034, as per GlobalData.
